1 December 2020 in Biochemistry and Biophysics Reports
Mitochondria oscillate along a morphological continuum from fragmented individual units to hyperfused tubular networks. Their position at the junction of catabolic and anabolic metabolism couples this morphological plasticity, called mitochondrial dynamics, to larger cellular metabolic programs, which in turn implicate mitochondria in a number of disease states. In many cancers, fragmented mitochondria engage the cell with the biosynthetic capacity of aerobic glycolysis in service of proliferation and progression. Chemo-resistant cancers, however, favor remodeling dynamics that yield fused mitochondrial assemblies utilizing oxidative phosphorylation (OXPHOS) through the electron transport chain (ETC). In this study, expression of Mitofusin-2 (MFN-2), a GTPase protein mediator of mitochondrial fusion, was found to closely correlate to Jurkat leukemia cell survival post doxorubicin (DxR) assault. Moreover, this was accompanied by dramatically increased expression of OXPHOS respiratory complexes and ATP Synthase, as well as a commensurate escalation of state III respiration and respiratory control ratio (RCR). Importantly, CRISPR knockout of MFN-2 resulted in a considerable decrease of doxorubicin (DxR) median lethal dose compared to a treated wildtype control, suggesting an important role of mitochondrial fusion in chemotherapy sensitivity and acute resistance.
1 May 2023 in The Journal of Immunology
GPR65 has been shown to be a critical regulator of Th17 pathogenicity. Loss of GPR65 in mice results in a decrease in Th17 cells and reduced susceptibility to experimental autoimmune encephalomyelitis. The CREB/CRTC2 pathway has emerged as an important regulator of immune function. We have previously shown that the CREB/CRTC2 pathway modulates autoimmune disease by promoting differentiation of Th17 cells. In this study we performed RNA-seq to identify Th17 genes regulated by the CREB/CRTC2 pathway. Our RNA-seq analysis led us to uncover the first mechanism of regulation of the orphan receptor GPR65 by the CREB/CRTC2 pathway. We show that GPR65 is a target of the CREB/CRTC2 pathway through expression studies and chromatin immunoprecipitation. In addition, we show that targeting of GPR65 with small molecules alters Th17 cell differentiation. Understanding the regulation of GPR65 will be crucial in developing small molecules to treat patients with Th17-mediated diseases.
1 March 2008 in The FASEB Journal
Autoimmune disease often occurs via the escape of autoreactive T cells from apoptosis, implying a breakdown of central or peripheral tolerance mechanisms. We have recently demonstrated that thymocytes and T cells lacking the serine/threonine kinase DRAK2 have a diminished activation threshold, suggesting that this kinase serves as a quiescence factor to maintain tolerance to weak self‐antigens. Drak2 −
/
− T cells produce higher levels of the cytokine IL‐2 and exhibit enhanced sensitivity to TCR mediated stimulation. Surprisingly, Drak2 −
/
− mice are resistant to experimental autoimmune encephalomyelitis (EAE). EAE is a disease induced in mice by immunization with MOG 35–55 peptide, which elicits multiple sclerosis‐like symptoms due to T cell activation and recruitment into the CNS. We have observed enhanced apoptosis in effector T cells derived from Drak2 −
/
− mice, suggesting that DRAK2 serves as both a quiescence factor in naïve T cells and a survival factor in effector T cells. T cells from MOG 35–55 ‐immunized DRAK2‐deficient mice have decreased levels of interferon gamma, IL‐17, and increased regulatory T cells (Treg) compared to wild‐type mice. We hypothesize that the decrease in these cytokines and increase in Treg is due to the increase in apoptosis of the effector cells. In accord with this, sensitivity to MOG 35–55 peptide induced EAE was rescued in DRAK2 −
/
− mice by a T cell‐specific Bcl‐ xL transgene, demonstrating that the resistance to this disease is a consequence of defective survival of MOG‐specific T cells. These results highlight the potential for inhibiting autoimmunity without affecting anti‐pathogen responsiveness via DRAK2 blockade. This work was supported by NIH grant R01 AI063419.